trending Market Intelligence /marketintelligence/en/news-insights/trending/k2022ppQgz4oiadPjXNryg2 content esgSubNav
In This List

Bio-Path Holdings raises $18.5M for working capital

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Bio-Path Holdings raises $18.5M for working capital

Bio-Path Holdings Inc., which develops cancer medicines, closed an $18.5 million registered direct offering.

The Bellaire, Texas-based biotechnology company sold 712,910 common shares at $25.95 apiece.

Bio-Path said it planned to use the net proceeds from the offering for working capital and general corporate purposes.

H.C. Wainwright & Co. was exclusive placement agent for the offering.

Bio-Path's lead product candidate, prexigebersen, is being studied in a phase 2 trial for blood cancers and is in preclinical studies for solid tumors.